Table 2.
Rifaximin and lactulose administration by analysis group
| Altered Mental Status/HE | Respiratory Failure/Cardiovascular-Instability | Procedure | All Patients | |
|---|---|---|---|---|
|
| ||||
| n | 70 | 150 | 94 | 314 |
| 24-h prior to intubation | ||||
| Patients given Rifaximin (%) | 16 (22.9) | 48 (32.0) | 14 (14.9) | 78 (24.8) |
| Lactulose enema received (%) | 5 (7.1) | 12 (8.0) | 5 (5.3) | 22 (7.0) |
| Patients given Lactulose PO1 (%) | 36 (51.4) | 68 (45.3) | 26 (27.7) | 130 (41.4) |
| Lactulose PO1 median number of doses2,3 [IQR] | 6 [2.75,10] | 5.5 [3, 8] | 2 [2, 4] | 4 [2, 8] |
| 24-h post-intubation | ||||
| Patients given Rifaximin (%) | 41 (58.6) | 65 (43.3) | 20 (21.3) | 126 (40.1) |
| Lactulose enema received (%) | 12 (17.1) | 11 (7.3) | 12 (12.8) | 35 (11.1) |
| Patients given Lactulose PO1 (%) | 24 (34.3) | 51 (34.0) | 11 (11.7) | 86 (27.4) |
| Lactulose PO1 median number of doses2,3 [IQR] | 10 [6.75,12.5] | 6 [4, 10] | 3 [2, 7] | 8 [4,11.5] |
1
Oral administration
2
Calculated based only on patients that received the treatment
3
1 dose Lactulose: 10 g